Drug intelligence / Profile preview

nanaomycin a

Development stage: Preclinical
Modality: Small Molecules
Administration: In Vitro Experimental, Not Established For Clinical Use

Overview

Nanaomycin A is a naturally-derived small molecule antibiotic and the first selective inhibitor of DNA methyltransferase 3B (DNMT3B), exhibiting an IC50 of approximately 500 nM. As a quinone antibiotic, it downregulates DNA methylation and reactivates silenced tumor suppressor genes by demethylating their promoters, notably RASSF1A, making it a promising epigenetic modulator for cancer research. Nanaomycin A shows antiproliferative effects on various human cancer cell lines and induces apoptosis in neuroblastoma cells, indicating a therapeutic potential for cancer, particularly neuroblastoma and other DNMT3B-driven tumors[1][3][4][8].

Other names: nanafrocinnanafrocinenanafrocinumrosanomycin a

Targets

DNMT3B (DNA (cytosine-5)-methyltransferase 3B)

Beyond the preview

Go deeper on nanaomycin a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nanaomycin a.

Explore the full profile